Trial Profile

A phase 2a study of HT-6184 in low-risk myelodysplastic syndrome patients

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HT-6184 (Primary) ; Darbepoetin alfa; Epoetin alfa
Indications Myelodysplastic syndromes
Focus Therapeutic Use

Most Recent Events

10 Dec 2024 Topline data presented in a Halia Therapeutics media release.
10 Dec 2024 According to a Halia Therapeutics media release, trial is expected to conclude by the end of Q2 2025. The results of this study are anticipated to provide pivotal data to support HT-6184's continued clinical development and eventual regulatory submission.
16 Jun 2024 Trial designs of this study were presented at the 29th Congress of the European Haematology Association.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com